Athira Pharma raises $90 million as Bothell firm shifts focus
Bothell-based Athira Pharma is raising $90 million as it shifts its primary focus from neurological diseases to breast cancer.
The company announced a $90 million private placement alongside a licensing agreement with Sermonix Pharmaceuticals for the Phase 3 breast cancer drug lasofoxifene, with clinical data expected in mid-2027. “Today marks a defining moment for our company,” said Athira CEO Mark Litton. “This agreement for the rights to the Phase 3 lasofoxifene program for metastatic breast cancer is a significant step in building a pipeline with the potential to change lives and create enduring value.”
The financing supports Athira’s strategic shift toward oncology and advances efforts to expand future treatment options for patients with breast cancer.